Why is Alembic Pharma falling/rising?

As of 08-Jul, Alembic Pharmaceuticals Ltd. is currently priced at 998.60, reflecting a decrease of 1.4 points or 0.14%. The stock has outperformed its sector by 0.79% today, although it has shown a decline of 1.58% over the past week, while gaining 1.43% over the past month. Despite a strong ability to service debt indicated by a low Debt to EBITDA ratio of 0.67 times and attractive valuation metrics, the stock's performance is hindered by a significant drop in investor participation, with delivery volume falling by 83.52% against the 5-day average. Additionally, while the stock has generated a return of 1.74% over the past year, its profits have decreased by 7%, contributing to a perception of poor long-term growth.
In the broader market context, Alembic Pharmaceuticals' recent performance contrasts with the Sensex, which has seen a slight increase of 0.02% over the past week and a more substantial gain of 1.85% over the past month. The stock's year-to-date decline of 5.72% starkly contrasts with the Sensex's rise of 7.13%, indicating that while the company has some positive attributes, such as high institutional holdings and a discount compared to peers, the overall market sentiment and recent negative financial results are impacting its stock price negatively.